AstraZeneca's Cancer Drug Suit In Wrong Venue, Mylan Says
Mylan Pharmaceuticals Inc. has said it will ask a New Jersey federal judge to dismiss AstraZeneca's patent suit over the generic-drug maker's attempt to market a generic version of its Faslodex...To view the full article, register now.
Already a subscriber? Click here to view full article